1 February 2019


previous arrow
next arrow

ADIENNE aims to establish Begesand® as standard treatment for acute Graft-versus-Host Disease (aGvHD), a life threatening disease caused by the reaction of the donor immune cells against the recipient’s tissue antigens (alloreaction) for which currently no approved drug and no universally accepted standard of care exists.

Begesand® is ADIENNE’s lead clinical product candidate. ADIENNE is currently running a Phase II clinical trial in acute Graft-versus-Host Disease to confirm the efficacy and safety of the product in such indication.

In parallel, ADIENNE is in process to start a phase II clinical trial to develop Begesand® as first line therapy in the treatment of dermatomyositis, an idiopathic inflammatory myopathy characterized by typical skin lesions and skeletal muscle weakness, opening new horizons in the treatment of such disabling and often refractory disease.

Begesand® has been granted ODD for the treatment of GvHD in the U.S., E.U. and Switzerland.